Industrializing the analysis of imaging assays across R&D organizations with advanced data QC workflows and scalable, flexible deployment options

Basel, Switzerland — Genedata, a leading provider of enterprise software solutions for biopharma R&D, today announced the availability of Genedata Imagence^® 5.0. The latest version of the Bio-IT World award-winning platform has been developed in close collaboration with industry-leading biopharma companies, which are using Imagence to automate their HCS image analysis workflows and to integrate data across their instrument portfolio. Imagence 5.0 features a new set of algorithms that raise the bar on automated image analysis for an increasing number of standard HCS assays run routinely in biopharmaceutical laboratories. The new algorithms enable easy identification of quality issues, enhance reliability of analysis results, increase robustness of the analysis, and pave the way to deeper insights. Committed to continuous architecture advancement, version 5.0 features a full range of deployment options for scalable, efficient, and cost-effective computing for any organization and its specific IT environment.

New Algorithms Increase Result Reliability and Drive Deeper Insights

The deep learning-based Genedata Imagence platform advances HCS assays into production faster than classical analysis pipelines by automating time-consuming image analysis setup. In production, it consistently applies the same unbiased analysis across multiple production runs without the need for re-configuration and is faster than classical settings. Delivering quantifiable value by lowering the cost and reducing the time of bringing HCS assays into production and running their analysis, Imagence 5.0’s enhanced architecture increases system scalability with flexible options for global deployment on-premise, in the Cloud, or via a hybrid model. The new set of algorithms of Imagence 5.0 empowers biologists to:

•    identify data quality issues on a cell-by-cell basis – an industry-first;
•    improve the reliability of analysis results with new QC workflows;
•    enhance mechanistic insights by detecting cells showing unexpected phenotypes;
•    define new phenotype classes on the go and add them to the model for incremental learning; and
•    increase analysis across different assays for the most robust assay portfolio.

With Bio-IT World awards for Best Practices and Best in Show, Imagence is recognized for its groundbreaking AI-powered HCS image analysis innovations. Integral to the Genedata Ready-to-Run program, the platform is technology-agnostic, offering the highest degree of integration with leading instrument vendors on the market and with APIs that enable quick integration with instruments from additional providers as needed.

“Launched in 2018, Imagence is in its fifth full version and stands as the undisputed leader in deep learning-based HCS image analysis,” said Othmar Pfannes, Ph.D., CEO of Genedata. “We are committed to continually advancing the platform’s capabilities, use cases, and applications as we strengthen collaborations with several of the world’s top ten biopharma companies that have adopted Imagence.”

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

www.genedata.com
LinkedIn | Twitter | YouTube

The statements in this press release to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the company’s products and services. Readers are cautioned not to place undue reliance to forward-looking statements, which speak only as the date hereof. The Company undertakes no obligation to release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after date hereof or to reflect the occurrence of unanticipated events.

All Products and service names mentioned are trademarks of their respective companies.